Question 1

What is Imlifidase?

Accepted Answer

Imlifidase is a Other.

Question 2

How often does Imlifidase appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Imlifidase first tracked by Ergen?

Accepted Answer

First tracked on May 19, 2026.

Question 4

When was Imlifidase last mentioned in news?

Accepted Answer

Last active on May 19, 2026.

Question 5

What is Imlifidase's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Imlifidase in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Imlifidase?

Accepted Answer

SERB_Pharmaceuticals acquires Idefirix rights (May 19, 2026, 7 articles).

Question 8

How did the "SERB_Pharmaceuticals acquires Idefirix rights" event impact Imlifidase?

Accepted Answer

Imlifidase>>> is the key drug being acquired, a treatment for highly sensitized adult patients prior to kidney transplant, which will now be commercialized by SERB Pharmaceuticals>>> in specific regions.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.